XRCC5 and ovarian cancer: Combination disrupts PARP1-Ku80 complex, enhances NHEJ over HR in G2, increases DNA double-strand breaks, cell cycle arrest, and induces persistent apoptosis, offering an effective approach for HR-proficient ovarian cancers.